Sugi Predict

Sugi Predict / Targets / MAPK15

MAPK15

Mitogen-activated protein kinase 15 · Q8TD08 · MAPK15 on Sugi Atlas →

7,395 patent compounds predicted against MAPK15, 6,255 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Riviciclib Riviciclib (SCHEMBL290572) 1.00 2/20
Riviciclib Riviciclib (SCHEMBL291157) 1.00 2/20
Riviciclib Riviciclib (SCHEMBL665748) 1.00 2/20
Riviciclib Riviciclib (SCHEMBL665749) 1.00 2/20
Riviciclib Riviciclib (SCHEMBL290347) 0.98 2/20
Riviciclib Riviciclib (SCHEMBL663219) 0.98 2/20
Riviciclib Riviciclib (SCHEMBL663220) 0.98 2/20
SCHEMBL1179589 SCHEMBL1179589 0.85 2/20
SCHEMBL1179591 SCHEMBL1179591 0.85 2/20
SCHEMBL1180321 SCHEMBL1180321 0.85 2/20
SCHEMBL1180324 SCHEMBL1180324 0.85 2/20
SCHEMBL1180730 SCHEMBL1180730 0.84 2/20
SCHEMBL1180734 SCHEMBL1180734 0.84 2/20
SCHEMBL1180211 SCHEMBL1180211 0.82 2/20
SCHEMBL1180213 SCHEMBL1180213 0.82 2/20
SCHEMBL1180222 SCHEMBL1180222 0.82 2/20
SCHEMBL1180644 SCHEMBL1180644 0.82 2/20
SCHEMBL1180648 SCHEMBL1180648 0.82 2/20
SCHEMBL1179796 SCHEMBL1179796 0.81 2/20
SCHEMBL1179798 SCHEMBL1179798 0.81 2/20

Clinical trials — most relevant to MAPK15 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer PHASE3RECRUITING
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours PHASE1/PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma PHASE2ACTIVE_NOT_RECRUITING
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC PHASE2COMPLETED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies PHASE1RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma nanCOMPLETED
Histiocytic Disorder Follow-up Study nanRECRUITING
Effects of Mulberry Juice on Inflammatory Status and Clinical Symptoms in Patients With General Anxiety Disorder nanUNKNOWN
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPK15 binder may also engage these)

ProteinNameSimilarity
Q80Y86 — 1.000 Q80Y86 →
Q9Z2A6 — 1.000 Q9Z2A6 →
Q9WVS8 — 0.994 Q9WVS8 →
Q5R8Z4 — 0.992 Q5R8Z4 →
Q8WP28 — 0.990 Q8WP28 →
Q9Z188 — 0.990 Q9Z188 →
O75064 — 0.988 O75064 →
DYRK1B Dual specificity tyrosine-phosphorylation-regulated kinase 1B 0.988 landscape →
PAK4 Serine/threonine-protein kinase PAK 4 0.987 landscape →
Q4V793 — 0.987 Q4V793 →
B8Y466 — 0.987 B8Y466 →
A5PKJ4 — 0.986 A5PKJ4 →
Q9R0A5 — 0.986 Q9R0A5 →
P18265 — 0.986 P18265 →
Q3ULB5 — 0.986 Q3ULB5 →
Q0PKV7 — 0.985 Q0PKV7 →
NUAK2 NUAK family SNF1-like kinase 2 0.985 landscape →
Q3V016 — 0.985 Q3V016 →
GSK3A Glycogen synthase kinase-3 alpha 0.985 landscape →
Q8BHW9 — 0.985 Q8BHW9 →
TESK2 Dual specificity testis-specific protein kinase 2 0.985 landscape →
CAMKK2 Calcium/calmodulin-dependent protein kinase kinase 2 0.985 landscape →
Q6QMY5 — 0.985 Q6QMY5 →
Q3UIZ8 — 0.984 Q3UIZ8 →
D3ZG83 — 0.984 D3ZG83 →
Q80UW3 — 0.984 Q80UW3 →
O43896 — 0.984 O43896 →
Q8VDU5 — 0.984 Q8VDU5 →
Q03146 — 0.984 Q03146 →
Q2LGB3 — 0.984 Q2LGB3 →